Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

368

Enrollment

INDUSTRY

Sponsor class

Stopped The primary efficacy endpoint was not met

Conditions

Corneal Diseases
Cornea Transplant

Interventions

DRUG: LX201
OTHER: Placebo

Sponsor

Lux Biosciences, Inc.